Myasthenia Gravis: Multimedia

References

1. Strauss AJL, Seigal BC, Hsu KC. Immunofluorescence demonstration of a muscle binding complement fixing serum globulin fraction in Myasthenia Gravis. Proc Soc Exp Biol. 1960;105:184. [Medline].

2. Patric J, Lindstrom JM. Autoimmune response to acetylcholine receptor. Science. 1973;180:871. [Medline].

3. Evoli A, Tonali PA, Padua L. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. Oct 2003;126(Pt 10):2304-11. [Medline].

4. Sanders DB, Howard JF, Massey JM. Seronegative myasthenia gravis. Ann Neurol. 1987;22:126. [Medline].

5. Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C, eds. Myology: Basic and Clinical. 2nd ed. 1994;1769-1797. [Medline].

6. Jaretzki A, Barohn RJ, Ernstoff RM. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. Jul 12 2000;55(1):16-23. [Medline].

7. Tindall RS. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol. Nov 1981;10(5):437-47. [Medline].

8. Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol. Sep 2005;116(9):2065-8. [Medline].

9. Romi F, Skeie GO, Gilhus NE. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol. Mar 2005;62(3):442-6. [Medline].

10. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol. Jan 2003;53(1):29-34. [Medline].

11. Meriggioli MN, Ciafaloni E, Al-Hayk KA. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. Nov 25 2003;61(10):1438-40. [Medline].

12. Lisak RP. Myasthenia Gravis. Curr Treat Options Neurol. Jul 1999;1(3):239-250. [Medline].

13. Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. Aug 21 2008;38(3):1101-1107. [Medline].

14. Argov Z, Wirguin I. Drugs and the neuromuscular junction: Pharmacotherapy of transmission disorders and drug-induced myasthenic syndromes. In: Lisak RP, ed. Handbook of Myasthenia Gravis and Myasthenic syndromes. 1994:295-319.

15. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci. 1981;377:652-69. [Medline].

16. Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol. Jul 22 2008;[Medline].

17. Kurtzke JE, Kurland LT. Epidemiology of neurologic disease. In: Baker AB, Baker LH, eds. Clinical Neurology. Philadelphia: Harper & Row;1982:47-49. [Medline].

18. Lewis RA, Lisak RP. "Rebooting" the immune system with cyclophosphamide:taking risks for a "cure"?. Ann Neurol. 2003;53:7-9. [Medline].

19. Limburg PC, The TH, Hummel-Tappel E. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci. Mar 1983;58(3):357-70. [Medline].

20. Mantegazza R, Beghi E, Pareyson D. A multicenter follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol. 1990;237:339-44. [Medline].

21. Massey JM. Acquired myasthenia gravis. Neurol Clinics. 1997;15(3):577-595. [Medline].

22. Medical Economics. 2005 Physicians' Desk Reference (PDR). Thomson Healthcare;2004.

23. Oh S. Single fiber electromyography in various diseases. In: Oh SJ, ed. Electromyography: Neuromuscular Transmission Studies. Baltimore;254. [Medline].

24. Oosterhuis HJ, Limburg PC, Hummel-Tappel E. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci. Mar 1983;58(3):371-85. [Medline].

25. Osserman KE. Myasthenia Gravis. New York: Grune and Stratton;1958:78-79,86-87. [Medline].

26. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med. Nov-Dec 1971;38(6):497-537. [Medline].

27. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. Dec 23 2003;61(12):1652-61. [Medline].

28. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. Jun 24 2003;60(12):1978-80. [Medline].

29. Wittbrodt ET. Drugs and myasthenia gravis. An update. Arch Intern Med. Feb 24 1997;157(4):399-408. [Medline].

Further Reading

Keywords

myasthenia gravis, autoimmune neuromuscular disease, skeletal muscle weakness, fatigability on exertion, muscle weakness, acetylcholine receptor, AChR, seronegative myasthenia gravis, SNMG, muscle-specific kinase, MuSK, MG

Contributor Information and Disclosures

Author

Aashit K Shah, MD, Associate Professor of Neurology, Wayne State University; Program Director, Clinical Neurophysiology Fellowship, Department of Neurology, Detroit Medical Center
Aashit K Shah, MD is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, and American Epilepsy Society
Disclosure: Nothing to disclose.

Medical Editor

Donald B Sanders, MD, EMG Laboratory Director, Professor of Medicine (Neurology), Division of Neurology, Duke University Medical Center
Donald B Sanders, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Neurological Association, and New York Academy of Sciences
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Glenn Lopate, MD, Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Chief of Neurology, St Louis ConnectCare, Consulting Staff, Barnes Jewish Hospital
Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa
Disclosure: Nothing to disclose.

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants
Nicholas Y Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Neurology
Disclosure: Nothing to disclose.